Kenvue is facing numerous challenges, with its stock down 20% this year due to concerns about Tylenol and other issues. However, the company could see a turnaround in 2026, driven by new leadership and potential catalysts for growth.

Kenvue, formerly part of Johnson & Johnson, became an independent company in 2023. It owns popular consumer health brands like Band-Aid and Listerine, generating billions in sales and profits annually.

Despite its strong brand portfolio, Kenvue has struggled with flat sales and declining profits. Activist investors have pushed for changes, leading to a new management team and strategic focus on unlocking shareholder value.

To boost its stock price, Kenvue is considering selling its skin health business for billions, which could provide cash for acquisitions. Positive developments around Tylenol and growth initiatives could also drive a recovery in the company’s shares.

Investors should consider the potential for a turnaround in Kenvue’s stock price, as the company implements changes to improve its performance and unlock value for shareholders. The company’s actions could lead to significant upside in the coming year.

Read more at Yahoo Finance: Meet the 5%-Yielding Dividend Stock That Could Soar in 2026